Johnson & Johnson vaccine ‘neutralizes’ Delta variant, new study finds
A ray of hope has been provided in the quest to prevent the highly contagious Delta variant from triggering a damaging third wave in the UK and elsewhere in the world.
Johnson & Johnson reports that its single-injection vaccine has shown great promise against the strain in a lab study.
Analysis of the blood of eight patients showed that the vaccine-induced immune responses against the Delta variant, first identified in India, were at a higher level than against the Beta variant, which was first identified. times in South Africa.
“We believe our vaccine provides long-lasting protection against COVID-19 and triggers neutralizing activity against the Delta variant,” said Johnson & Johnson Scientific Director Paul Stoffels.
J&J submitted the data as a preprint on the bioRxiv website, prior to peer review.
And in another boost, data from a separate study also showed that the immune response of vaccine recipients lasted for at least eight months.
“Johnson & Johnson Single Injection COVID-19 Vaccine Generates Strong Neutralizing Antibody Response That Does Not Weaken; rather we see improvement over time, ”said Mathai Mammen, head of research and development at J & J’s Drugs.
So far, preliminary data has shown that vaccines made by Pfizer, AstraZeneca (AZN.L) and Moderna (MRNA.O) are largely protective against Delta, with the concentration of virus neutralizing antibodies being somewhat reduced.